Health TidingsZealand Reports Positive Multiple-Dose Safety Results for Kv1.3 Blocker ZP9... Zealand Reports Positive Multiple-Dose Safety Results for Kv1.3 Blocker ZP9... Read Post »
Health TidingsIfupinostat Achieves 36.5% Response Rate in DLBCL, but Median PFS Is 2.7 Mo... Ifupinostat Achieves 36.5% Response Rate in DLBCL, but Median PFS Is 2.7 Mo... Read Post »
Health TidingsMabwell 9MW2821 Shows 30% Response Rate in TNBC Mabwell 9MW2821 Shows 30% Response Rate in TNBC Read Post »
Clinical TrialsZentalis Reports 15.8-Month Median Survival With Azenosertib in Cyclin E1-P... Zentalis Reports 15.8-Month Median Survival With Azenosertib in Cyclin E1-P... Read Post »
Health TidingsGT801 Wins FDA Orphan Drug Designation for AIHA GT801 Wins FDA Orphan Drug Designation for AIHA Read Post »
Clinical TrialsANKTIVA Plus BCG Delivers Lasting Responses, with 84.2% Cystectomy-Free Sur... ANKTIVA Plus BCG Delivers Lasting Responses, with 84.2% Cystectomy-Free Sur... Read Post »
Clinical TrialsAbbVie Reports Long-Term Remission Data for SKYRIZI and RINVOQ in IBD AbbVie Reports Long-Term Remission Data for SKYRIZI and RINVOQ in IBD Read Post »
New Drug ApprovalViatris Wins FDA Approval for RYZUMVI to Treat Presbyopia in Adults Viatris Wins FDA Approval for RYZUMVI to Treat Presbyopia in Adults Read Post »
GenericsFDA Approves Alcon’s Brytly Eye Drops for Redness Relief FDA Approves Alcon’s Brytly Eye Drops for Redness Relief Read Post »
Clinical TrialsCyrano’s CYR-064 Improves Smell Loss in Phase 2 Trial Cyrano’s CYR-064 Improves Smell Loss in Phase 2 Trial Read Post »
Health TidingsAscendis Navepegritide Wins Positive CHMP Opinion Ascendis Navepegritide Wins Positive CHMP Opinion Read Post »
New Drug ApprovalUCB Wins FDA Approval for ZILBRYSQ Autoinjector With 99.8% Dose Delivery UCB Wins FDA Approval for ZILBRYSQ Autoinjector With 99.8% Dose Delivery Read Post »
Clinical TrialsOrganon Presents Six-Year MIUDELLA Results to Support Longer Contraceptive ... Organon Presents Six-Year MIUDELLA Results to Support Longer Contraceptive ... Read Post »
Health TidingsEMA Maintains Negative Opinion on Narsoplimab for TA-TMA EMA Maintains Negative Opinion on Narsoplimab for TA-TMA Read Post »
Clinical TrialsKrystal’s KB113 Shows 83% BCC Regression in Gorlin Syndrome Krystal’s KB113 Shows 83% BCC Regression in Gorlin Syndrome Read Post »
Health TidingsEarlier-Line TALVEY Use Moves Forward After Positive European Recommendatio... Earlier-Line TALVEY Use Moves Forward After Positive European Recommendatio... Read Post »
Health TidingsEstuary Biotherapeutics Debuts With $103M for ADPKD Gene Therapies Estuary Biotherapeutics Debuts With $103M for ADPKD Gene Therapies Read Post »
Health TidingsRevMed’s RASONQUE Moves Closer to EU Approval for PDAC RevMed’s RASONQUE Moves Closer to EU Approval for PDAC Read Post »
Health TidingsMHRA Strengthens Antidepressant Safety Warnings on Suicide Risk and Sexual ... MHRA Strengthens Antidepressant Safety Warnings on Suicide Risk and Sexual ... Read Post »
Clinical TrialsEisai Reports Improved Disease Control With Belzutifan-LENVIMA in RCC Eisai Reports Improved Disease Control With Belzutifan-LENVIMA in RCC Read Post »
New Drug ApprovalRoche Wins FDA Approval for Enspryng Despite Mixed Phase III Results Roche Wins FDA Approval for Enspryng Despite Mixed Phase III Results Read Post »
Clinical TrialsOpus Reports BEST1 Retinal Sensitivity Gains and Sustained LCA5 Vision Impr... Opus Reports BEST1 Retinal Sensitivity Gains and Sustained LCA5 Vision Impr... Read Post »
Regulatory & Health PolicyFDA Launches Cross-Center Framework to Standardize Rare Disease Drug Review FDA Launches Cross-Center Framework to Standardize Rare Disease Drug Review Read Post »
Clinical TrialsOsivax OVX836 Misses Phase 2b Influenza Vaccine Target Osivax OVX836 Misses Phase 2b Influenza Vaccine Target Read Post »
Clinical TrialsGalderma Reports Positive Itch Response for Nemolizumab in Young Children Galderma Reports Positive Itch Response for Nemolizumab in Young Children Read Post »
Clinical TrialsEC-104 Shows Durable Improvement in Phase 2 DME Trial EC-104 Shows Durable Improvement in Phase 2 DME Trial Read Post »
Clinical TrialsLilly’s Omvoh Achieves Deeper Remission in IBD Lilly’s Omvoh Achieves Deeper Remission in IBD Read Post »
Health Tidings Mergers & AcquisitionsAdlai Nortye Partners with Eli Lilly and Merck KGaA for Phase I ADC Combina... Adlai Nortye Partners with Eli Lilly and Merck KGaA for Phase I ADC Combina... Read Post »
Clinical TrialsinvIOs’ APN401 Shows Early Safety Findings and Disease Stabilization in A... invIOs’ APN401 Shows Early Safety Findings and Disease Stabilization in A... Read Post »
Health TidingsAquestive’s Anaphylm NDA Resubmission Accepted by FDA Aquestive’s Anaphylm NDA Resubmission Accepted by FDA Read Post »
Clinical TrialsCellectar’s Iopofosine I 131 Shows 87.5% Response Rate in WM Cellectar’s Iopofosine I 131 Shows 87.5% Response Rate in WM Read Post »
Health TidingsAstraZeneca, insitro Strike $1.5 Billion AI Drug Discovery Deal for MASH an... AstraZeneca, insitro Strike $1.5 Billion AI Drug Discovery Deal for MASH an... Read Post »
Health TidingsVividion Advances WRN Inhibitor VVD-214 Into Phase 2 Trial with Pembrolizum... Vividion Advances WRN Inhibitor VVD-214 Into Phase 2 Trial with Pembrolizum... Read Post »
Health TidingsSarepta’s SRP-1003 Achieves Up to 80% Nuclear DMPK RNA Knockdown in Precl... Sarepta’s SRP-1003 Achieves Up to 80% Nuclear DMPK RNA Knockdown in Precl... Read Post »
Health TidingsPonatinib Plus Blinatumomab Improves 24-Month Event-Free Survival in Ph-Pos... Ponatinib Plus Blinatumomab Improves 24-Month Event-Free Survival in Ph-Pos... Read Post »
Health TidingsElevar Resubmits Rivoceranib-Camrelizumab NDA After Three FDA CRLs, Despite... Elevar Resubmits Rivoceranib-Camrelizumab NDA After Three FDA CRLs, Despite... Read Post »
New Drug ApprovalFDA Expands ANKTIVA Approval to High-Grade Papillary-Only Bladder Cancer FDA Expands ANKTIVA Approval to High-Grade Papillary-Only Bladder Cancer Read Post »
Clinical TrialsZenas Obexelimab Show Sustained Flare Control, Reduced Steroid Toxicity in ... Zenas Obexelimab Show Sustained Flare Control, Reduced Steroid Toxicity in ... Read Post »
Clinical TrialsVanda VQW-765 Phase 3 Trial Fails in Social Anxiety Vanda VQW-765 Phase 3 Trial Fails in Social Anxiety Read Post »
Clinical TrialsArrowhead ARO-MAPT Cuts CSF Tau by 73% in Phase 1/2a Arrowhead ARO-MAPT Cuts CSF Tau by 73% in Phase 1/2a Read Post »
Health TidingsFDA Accepts Tabelecleucel Resubmission for EBV-Positive PTLD FDA Accepts Tabelecleucel Resubmission for EBV-Positive PTLD Read Post »
Clinical TrialsSitryx Reports Early Improvements in Atopic Dermatitis With SYX-5219 Sitryx Reports Early Improvements in Atopic Dermatitis With SYX-5219 Read Post »
Clinical TrialsTAK-881 Meets Primary PK Endpoint, Reducing Infusion Burden in PID TAK-881 Meets Primary PK Endpoint, Reducing Infusion Burden in PID Read Post »
Health TidingsVir and Gilead Partner on T-Cell Engagers for Solid Tumors Vir and Gilead Partner on T-Cell Engagers for Solid Tumors Read Post »
Health TidingsUnited Therapeutics Presents PAH, IPF and PH-ILD Data at CHEST 2026 United Therapeutics Presents PAH, IPF and PH-ILD Data at CHEST 2026 Read Post »
Health TidingsBMS Reports Phase 3 PFS Benefit with RYZ101 in Advanced GEP-NETs BMS Reports Phase 3 PFS Benefit with RYZ101 in Advanced GEP-NETs Read Post »
Health TidingsAlentis and PinotBio Expand Claudin-1 ADC Development Alentis and PinotBio Expand Claudin-1 ADC Development Read Post »
Clinical TrialsEntrada Reports Early Dystrophin Increase with ENTR-601-45 in DMD Entrada Reports Early Dystrophin Increase with ENTR-601-45 in DMD Read Post »
Clinical TrialsVerastem’s VS-7375 Shows 50% Response Rate in Pancreatic Cancer Verastem’s VS-7375 Shows 50% Response Rate in Pancreatic Cancer Read Post »
Health Tidings Mergers & AcquisitionsEton Secures U.S. Rights to LIBERVANT Seizure Rescue Film Eton Secures U.S. Rights to LIBERVANT Seizure Rescue Film Read Post »
